Oxcia - pre-IPO private placement of SEK 70m
Oxcia is a clinical stage drug development company with two DDR (DNA Damage and Repair) drug candidates targeting cancer and fibrosis. DDR is an emerging and prioritized scientific area with numerous big pharma companies investing in the field and several recent large M&A-deals. The proceeds will be used to finance finalization of two clinical phase I studies with read-out in 2021.
We thank Oxcia for the vote of confidence and congratulate on the successful transaction!
Latest news
Arctic Securities - IMPORTANT NOTICE — ARCTICSAS
Arctic Securities is not affiliated with "Arctic SAS" or www.arcticsas.com.
We have been made aware that unknown parties are using the Arctic Securities name, logo and trademark in connection with investment offers directed at private individuals abroad.
Arctic Securities - Arctic Securities ramps up its Swedish operations
Arctic Securities ramps up its Swedish operations with new key hires in Stockholm to strengthen its full-service Nordic investment bank offerings. Gustav Rosén will assume the role of CEO Sweden.
Arctic Securities - TÝR Markets and Arctic Securities form a collaboration
TÝR Markets and Arctic Securities form a collaboration providing clients access to selected digital assets in a fast-growing market
Arctic Securities - Strong Attendance and Clear Demand Signals at the Arctic Seafood Conference 2025
Arctic Securities welcomed nearly 400 participants to this year’s Arctic Seafood Investor Conference at Hotel Continental, where global demand dynamics took centre stage.
Arctic Securities - Arctic med flere pallplasser og størst vekst på meglerbordet
Arctic Securities tar ni pallplasser i Kapitals årlige meglerhuskåring, med Norges beste aksjemeglere og størst vekst på meglerbordet.
Arctic Securities - Arctic top-ranked in Prospera 2025
Arctic Securities secured several leading positions in the Prospera Nordic High Yield Investor Survey 2025.